Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
1998
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
2000
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
1992
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
1997
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer
1994
Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen
2003
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
1995
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
1991
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
2003
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
2001
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
1995
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
c- erb B-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent
2004
ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
1996
The relationship between prognostic and predictive factors in the management of breast cancer
1998
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
1999
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
2001
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer
1997
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
1997
Prognostic Factors in Breast Cancer
2000
Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma
1998
EGFR Antagonists in Cancer Treatment
2008 Standout
Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
1991
ErbB-targeted therapeutic approaches in human cancer
2003
Oncogenic kinase signalling
2001 StandoutNature
Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
1994
Growth factors and oncogenes in breast cancer
1990
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 Standout
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 Standout
Renal-Cell Carcinoma
1996 Standout
Signal transduction by receptors with tyrosine kinase activity
1990 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
MINIREVIEW: Estrogen Receptor Variants in Clinical Breast Cancer
1991
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
1992
Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells
2003
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche
2004 Standout
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer
1997
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
1994
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The molecular biology of breast cancer
1991
The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors
1996
Inflammation and cancer: back to Virchow?
2001 Standout
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
1992
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Tumor angiogenesis in node-negative breast carcinomas ? relationship with epidermal growth factor receptor, estrogen receptor, and survival
1994
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Angiogenesis and Blood Vessel Invasion as Prognostic Indicators for Node-Negative Breast Cancer
2001
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer
2000
GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES
1988
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
1994
The epidermal growth factor receptor as a target for therapy in breast carcinoma
1994
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1997 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
1991
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast
1999
Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and theor relation to estradiol receptor (ER) status
1997
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
1998
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
1998 Standout
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
2006 Standout
Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines
1999 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Head and Neck Cancer
2001 Standout
Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
1992
Cancer of the Ovary
2004 Standout
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
2006
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
1993 StandoutNobel
Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo.
2001
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor, c‐erbB‐2 protein, estrogen receptor related protein, p21‐ras protein, and proliferation indicators in relation to tumor recurrences and patient survival
1995
Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node–Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables
2001
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Hirudin in Acute Myocardial Infarction
1996
Prognostic value of epidermal growth factor receptor expression in cervical carcinoma.
1993
Type 1 growth factor receptors: an overview of recent developments
1995
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
1990 StandoutScience
Regulation of cell surface beta 1 integrin levels during keratinocyte terminal differentiation.
1995
Associations between gene expressions in breast cancer and patient survival
2002
Growth Factors and Cancer
1991 StandoutScience
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.
1992
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia
2002
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
1989 StandoutScience
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
1995 StandoutScience
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
1999
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
2002
Works of S Nicholson being referenced
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
1992
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
1989
Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
1989
Epidermal growth factor receptor status of histological sub-types of breast cancer
1988
Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
1990
Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut‐off points of clinical relevance
1988
Relationships between oestrogen receptor, epidermal growth factor receptor, ER‐D5, and P24 oestrogen regulated protein in human breast cancer
1988
Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer
1988
pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response
1991
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER
1989
Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup
1991
Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study
1990
Measurement of oestrogen receptor mRNA levels in human breast tumours
1988
Epidermal growth factor receptors in human breast cancer
1988
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
1988
CORTICOTROPHIN, CORTISOL, PROLACTIN AND GROWTH HORMONE RESPONSES TO INSULIN‐INDUCED HYPOGLYCAEMIA IN NORMAL SUBJECTS GIVEN SODIUM VALPROATE
1985
EPIDERMAL GROWTH-FACTOR RECEPTOR - A MARKER OF EARLY RELAPSE IN BREAST-CANCER AND TUMOR STAGE PROGRESSION IN BLADDER-CANCER - INTERACTIONS WITH NEU
1989